Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Alliance Grants

University of Alberta

$25,000.00

Novel Glue for Embolization of Lymphatic Leakage

EF 2024-25

Résumé
Due to a high success rate, and minimal complications, thoracic duct embolization is becoming a common intervention to treat lymphatic leakage. Existing liquid embolization materials require slow delivery that can last up to an hour, unpredictable in situ polymerization that leads to several adverse effects, solvents with a myriad of potential physiological interactions, and high cost (e.g., $4,000/ml). Here, we propose a novel sealant that improves upon current treatments in the following respects: 1) Provides an optimized delivery window, 2) Does not require in situ polymerization, 3) Avoids potentially harmful byproducts and solvents, and 4) Cost effective. The objective of the proposal is to develop "smart" hydrogel sealant that eliminates the disadvantages of the presently used glues. We propose to leverage the thermo-responsive properties of poly(N-isopropylacrylamide) (PNIPAM) to develop the glue material. PNIPAM which was first synthesized in 1956 as a smart biostable polymer investigated for a range of biomedical, drug screening, biotechnology, and medical diagnostics applications. The proposed hydrogel will optimize those properties for the embolization of lymphatic leaks. To do so effectively, it will accomplish the following: 1) Rely on a customized polymer conformation compatible with imaging agents while still transitioning to solid form at a target temperature, 2) Sufficiently radiopaque to allow visualization of the glue during delivery under fluoroscopy guidance, 3) Mechanical properties (viscosity, cohesiveness) suitable for delivery via 3Fr catheter, 4) Solidify after delivery with sufficient cohesion and adhesion to resist migration under physiological pressures, and 5) No toxicity as it does not polymerize in the body. Successful completion of the proposal will allow safe and durable embolization of lymphatic leaks with no permanent damage of surrounding tissue to advance the field of lymphatic embolization therapy. Our goal is to simultaneously optimize three components: 1) Access, 2) Quality and 3) Cost. The proposed glue material technology will have many other bio-medical applications. This high risk/high return proposal can improve current embolization biomaterial and hence improve the quality of therapy for many patients in need of embolization glues.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
597076-2024
Name nom
Narain, Ravin R
Department département
Chemical and Materials Engineering
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
25000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1208
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Materials sciences
Area of application fr
Sciences des matériaux
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Novel Glue for Embolization of Lymphatic Leakage
Keywords
biomaterials; biomedical glue; embolization; responsive polymers
Application summary
Due to a high success rate, and minimal complications, thoracic duct embolization is becoming a common intervention to treat lymphatic leakage. Existing liquid embolization materials require slow delivery that can last up to an hour, unpredictable in situ polymerization that leads to several adverse effects, solvents with a myriad of potential physiological interactions, and high cost (e.g., $4,000/ml). Here, we propose a novel sealant that improves upon current treatments in the following respects: 1) Provides an optimized delivery window, 2) Does not require in situ polymerization, 3) Avoids potentially harmful byproducts and solvents, and 4) Cost effective. The objective of the proposal is to develop "smart" hydrogel sealant that eliminates the disadvantages of the presently used glues. We propose to leverage the thermo-responsive properties of poly(N-isopropylacrylamide) (PNIPAM) to develop the glue material. PNIPAM which was first synthesized in 1956 as a smart biostable polymer investigated for a range of biomedical, drug screening, biotechnology, and medical diagnostics applications. The proposed hydrogel will optimize those properties for the embolization of lymphatic leaks. To do so effectively, it will accomplish the following: 1) Rely on a customized polymer conformation compatible with imaging agents while still transitioning to solid form at a target temperature, 2) Sufficiently radiopaque to allow visualization of the glue during delivery under fluoroscopy guidance, 3) Mechanical properties (viscosity, cohesiveness) suitable for delivery via 3Fr catheter, 4) Solidify after delivery with sufficient cohesion and adhesion to resist migration under physiological pressures, and 5) No toxicity as it does not polymerize in the body. Successful completion of the proposal will allow safe and durable embolization of lymphatic leaks with no permanent damage of surrounding tissue to advance the field of lymphatic embolization therapy. Our goal is to simultaneously optimize three components: 1) Access, 2) Quality and 3) Cost. The proposed glue material technology will have many other bio-medical applications. This high risk/high return proposal can improve current embolization biomaterial and hence improve the quality of therapy for many patients in need of embolization glues.